Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.

You may also be interested in...



Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Allergan has two oral CGRP inhibitors – the only small molecules in the drug class in the clinic – but anti-CGRP biologics are likely to hit the market first. However, an effective oral product from a company that’s already marketing a migraine drug – Botox – could be an overlooked contender.

Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.

Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex

Amgen Inc. and Novartis AG are busy shoring up the case for their CGRP inhibitor erenumab – which is in a race with three others to be the first on to the migraine market. Positive topline Phase II data with erenumab has been reported but analysts suggest they may not be as strong as those from its competitors. The four CGRP inhibitors are all in Phase III with late-stage data expected this year.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

SC063805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel